Standard Therapies - Cord Blood
|
|
|
- Bridget Stone
- 5 years ago
- Views:
Transcription
1 A healthy future is in your hands Standard Therapies - Cord Blood Clinical Trials with Blood - Forming Stem Cells Gene Therapy for Inherited Disorders Using Blood - Forming Stem Cells Clinical Trials with Cord Tissue Stem Cells
2 01 Standard Therapies - Cord Blood Anaemias Aplastic Anaemia Congenital Dyserythropoietic Anaemia Fanconi Anaemia Paroxysmal Nocturnal Haemoglobinuria (PNH) Leukaemia Acute Leukaemia Acute Lymphoblastic Leukaemia (ALL) Acute Myelogenous Leukaemia (AML) Acute Biphenotypic Leukaemia Acute Undifferentiated Leukaemia Chronic Leukaemia Chronic Myelogenous Leukaemia (CML) Chronic Lymphocytic Leukaemia (CLL) Juvenile Chronic Myelogenous Leukaemia (JCML) Juvenile Myelomonocytic Leukaemia (JMML) Myelodysplastic Syndromes (pre-leukaemia) Refractory Anemia (RA) Refractory Anemia with Ringed Sideroblasts (RARS) Refractory Anemia with Excess Blasts (RAEB) Refractory Anemia with Excess Blasts in Transformation (RAEB-T) Chronic Myelomonocytic Leukemia (CMML) Lymphomas Hodgkin's Lymphoma Non-Hodgkin's Lymphoma (Burkitt's Lymphoma) Bone Marrow Cancers (Plasma Cell Disorders) Multiple Myeloma Plasma Cell Leukaemia Waldenstrom's Macroglobulinemia Solid Tumors (originating outside the blood and immune system) Neuroblastoma Medulloblastoma Retinoblastoma
3 Continued Myeloproliferative Disorders Acute Myelofibrosis Agnogenic Myeloid Metaplasia (Myelofibrosis) Polycythemia Vera Essential Thrombocythemia Phagocyte Disorders Chediak-Higashi Syndrome Chronic Granulomatous Disease Neutrophil Actin Deficiency Reticular Dysgenesis Inherited Red Cell Abnormalities Beta Thalassemia Major Diamond-Blackfan Anemia Pure Red Cell Aplasia Sickle Cell Disease Inherited Platelet Abnormalities Amegakaryocytosis / Congenital Thrombocytopenia Glanzmann Thrombasthenia Inherited Metabolic Disorders Mucopolysaccharidoses (MPS) Storage Diseases Mucopolysaccharidoses (MPS) Hurler's Syndrome (MPS-IH) Scheie Syndrome (MPS-IS) Hunter's Syndrome (MPS-II) Sanfilippo Syndrome (MPS-III) Morquio Syndrome (MPS-IV) Maroteaux-Lamy Syndrome (MPS-VI) Sly Syndrome, Beta-Glucuronidase Deficiency (MPS-VII) Mucolipidosis II (I-cell Disease) Leukodystrophy Disorders Adrenoleukodystrophy (ALD) / Adrenomyeloneuropathy (AMN) Krabbe Disease (Globoid Cell Leukodystrophy) Metachromatic Leukodystrophy Pelizaeus-Merzbacher Disease
4 Continued Lysosomal Storage Diseases Niemann-Pick Disease Sandhoff Disease Wolman Disease Other Lesch-Nyhan Syndrome Osteopetrosis Inherited Immune System Disorders Severe Combined Immunodeficiency (SCID) SCID with Adenosine Deaminase Deficiency (ADA-SCID) SCID which is X-linked SCID with absence of T and B Cells SCID with absence of T Cells, Normal B Cells Omenn Syndrome Neutropenias Kostmann Syndrome Myelokathexis Other Ataxia-Telangiectasia Bare Lymphocyte Syndrome Common Variable Immunodeficiency DiGeorge Syndrome Hemophagocytic Lymphohistiocytosis Leukocyte Adhesion Deficiency Lymphoproliferative Disorders (LPD) Lymphoproliferative Disorder, X-linked Wiskott-Aldrich Syndrome Inherited Disorders effecting the Immune System and Other Organs Cartilage-Hair Hypoplasia Gunther's Disease (Erythropoietic Porphyria) Hermansky-Pudlak Syndrome Pearson's Syndrome Shwachman-Diamond Syndrome Systemic Mastocytosis
5 02 Clinical Trials with Blood - Forming Stem Cells Neurologic Disorder Cerebral Palsy Hypoxic Ischemic Encephalopathy (HIE) Spinal Cord Injury Autism Hearing Loss (acquired sensorineural) Autoimmune Disorders Amyotrophic Lateral Sclerosis (ALS) Crohn's Disease Diabetes Type 1 Graft-versus-Host-Disease (GVHD) Kidney Plus Stem Cell Transplant Lupus Multiple Sclerosis Rheumatiod Arthritis Scleroderma Cardiovascular Congenital Defects Support for Misc. Open Heart Surgery Hypoplastic Left Heart Syndrome (HLHS) Grow Vascular Graft Ischemia Critical Limb Ischemia (CLI) Compartment Syndrome (Battlefield Trauma) Ischemic stroke Ischemic Heart Disease Cardiac Repair Myocardial Infarction Cardiomyopathay
6 03 Gene Therapy for Inherited Disorders Using Blood - Forming Stem Cells Adrenoleukodystrophy Chronic Granulomatous Disease (X-linked) Fanconi Anemia HIV Metachromatic Leukodystrophy Severe Combined Immunodeficiency Thalassemia Sickle Cell Wiskott-Aldrich Syndrome Orthopedic Alveolar Cleft Palate Repair Knee Cartilage Repair Miscellaneous Epidermolysis Bullosa AIDS Lysosomal Storage Disease Bronchopulmonary Dysplasia (BPD) 04 Clinical Trials with Cord Tissue Stem Cells Alzheimer's Disease Aplastic Anemia Cerebral Palsy Diabetes, Type 2 Liver Failure Multiple Sclerosis Rheumatoid Arthritis Spinal Cord Injury Cartilage Repair Connective Tissue Diseases Erectile Dysfunction Lung Injury Lupus Muscular Dystrophy Myocardial Infarction Osteoarthritis Ovarian failure Parkinson s disease Psoriasis Retinitis pigmentosa Sepsis Stroke Traumatic optic neuropathy Ulcerative colitis
7 A healthy future is in your hands Future Health Technologies Limited 10 Faraday Building Nottingham Science & Technology Park University Boulevard Nottingham NG7 2QP United Kingdom Tel: Fax: Future Health Biobank S.A. Route de Pra de Plan Châtel-St-Denis Switzerland Tel: Fax: info@futurehealthbiobank.ch Future Health Technologies Limited DTL-INT-v3.1
INFORMATION KIT H PE. IS IN YOUR NEWBORN S BLOOD Help it last a lifetime with cord blood banking. Save $300 with Promo Code.
INFORMATION KIT H PE IS IN YOUR NEWBORN S BLOOD Help it last a lifetime with cord blood banking Save $300 with Promo Code Cord4Life CORD BLOOD STEM CELLS Umbilical cord blood is unique and is only available
Family Medical History Questionnaire (FMHQ)
First, Last Name DOB: Cord Blood Bank Use Only: Family Medical History Questionnaire (FMHQ) NMDP CBU ID: Local CBU ID: NMDP Maternal ID: Today's Date: Local Maternal ID: Baby's Mother's Initials: Please
CordLife Secures US Department of Defense Contract
THEGUARDIAN Year 2004 - Eighth Issue. Mita (P) 119/11/2002 A Newsletter from CordLife CordLife Secures US Department of Defense Contract CordLife announced that its Boston-based subsidiary, Cytomatrix
Donating your baby s cord to a public cord blood bank can save lives globally.
Donating your baby s cord to a public cord blood bank can save lives globally. You can play an important role in saving lives by donating the blood contained in your baby s umbilical cord to LifeCord,
What are stem cells? A stem cell can differentiate into any one of 220 different specialised cells in the body STEM CELLS
What are stem cells? Stem cells are often called MASTER CELLS, and form the foundation for your entire body as building blocks for the blood, immune system, tissue and organs. They can REPLICATE or REGENERATE
HEMATOPOIETIC CELL TRANSPLANTATION FOR GENETIC DISEASES AND ACQUIRED ANEMIAS
ACQUIRED ANEMIAS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are
Sub-Class Code Sub-Classification Other code. Bone Marrow failures including 7 Aplastic Anaemia 77 Other 1 Acquired. Pure red cell aplasia (non
ification Sub- Sub-ification code Absence of T & B cells SCID 8 Inherited Disorders 1 Primary immune deficiencies Absence of T, normal B cell SCID 8 Inherited Disorders 1 Primary immune deficiencies Acquired
Recommended Timing for Transplant Consultation
REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org
Corporate Medical Policy
Corporate Medical Policy Allogeneic Hematopoietic Transplant for Genetic Diseases and File Name: Origination: Last CAP Review: Next CAP Review: Last Review: allogeneic_hematopoietic_transplant_for_genetic_diseases
APBMT Registry LMD Disease classification sheet
AML ALL Other Acute Leukemias ACUT E LEUKEMIAS Unique Patient Number or Code: - - (yyyy - mm - dd) Classification (Check ONLY ONE): AML with recurrent genetic abnormalities Acute Lymphoblastic Leukemia
Applications of Cord Blood Stem Cells
Applications of Cord Blood Stem Cells over 360 families have used their banked cord blood in transplant or regenerative medicine research. 1 88 ViaCord has released over 360 units for transplant or infusion
a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation
a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation This resource has been developed to help guide you regarding the appropriate timing and conditions for a referral
July 3, The Physician Compare Team Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244
July 3, 2013 The Physician Compare Team Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 Re: Physician Compare Intelligent Search To Whom it May Concern, The American
4000: Cellular Therapy Essential Data Pre-Infusion Form
4000: Cellular Therapy Essential Data Pre-Infusion Form Registry Use Only Sequence Number: Date Received: Key Fields CIBMTR Center Number: Event date: / / CIBMTR Form 4000 revision 3 (page 1 of 19). Last
STEMCYTE INDIA s impeccable transplant record (Unmatched in Cord Blood industry)
STEMCYTE INDIA s impeccable transplant record (Unmatched in Cord Blood industry) 1 1 No. Patient Name Diseases Transplant Centers Cord Blood Volume in ml 1 Patient 1 RELAPSED BILINEAGE LEUKEMIA HLA match
12 Dynamic Interactions between Hematopoietic Stem and Progenitor Cells and the Bone Marrow: Current Biology of Stem Cell Homing and Mobilization
Table of Contents: PART I: Molecular and Cellular Basis of Hematology 1 Anatomy and Pathophysiology of the Gene 2 Genomic Approaches to Hematology 3 Regulation of Gene Expression, Transcription, Splicing,
Give Birth to Hope: An Unique Approach to Public Cord Blood Donation
Give Birth to Hope: An Unique Approach to Public Cord Blood Donation The Public Health Nursing and Professional Development Unit, North Carolina Division of Public Health, is approved as a provider of
BMTCN Review Course Basic Concepts and Indications for Transplantation How the Experts Treat Hematologic Malignancies Las Vegas, NV, March 10, 2016
BMTCN Review Course Basic Concepts and Indications for Transplantation How the Experts Treat Hematologic Malignancies Las Vegas, NV, March 10, 2016 David Rice, PhD, RN, NP Director, Professional Practice
Allogeneic Hematopoietic Cell Transplantation for Genetic Diseases and Acquired Anemias
Allogeneic Hematopoietic Cell Transplantation for Genetic Diseases and Acquired Anemias Policy Number: Original Effective Date: MM.07.001 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO
MP Allogeneic Hematopoietic Cell Transplantation for Genetic Diseases and Acquired Anemias
Medical Policy MP 8.01.22 BCBSA ef. Policy: 8.01.22 Last eview: 01/30/2018 Effective Date: 01/30/2018 Section: Therapy elated Policies 8.01.25 Hematopoietic Cell Transplantation for Autoimmune Diseases
Clinical Utility. Clinical Utility of the Automated IG-Count Xavier Troussard
5. Clinical Utility Clinical Utility of the Automated IG-Count Xavier Troussard Introduction Quantitative analysis of immature granulocytes (IG) is useful for the optimal clinical and biological management
The primary medical content categories of the blueprint are shown below, with the percentage assigned to each for a typical exam:
Hematology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified hematologist
A GLOBAL REGENERATIVE THERAPEUTICS COMPANY. A Commitment to EXCELLENCE. IMPECCABLE TRANSPLANT RECORD Unmatched in cord blood industry
A GLOBAL REGENERATIVE THERAPEUTICS COMPANY A Commitment to EXCELLENCE IMPECCABLE TRANSPLANT RECORD Unmatched in cord blood industry IT HAPPENS ONLY IN STEMCYTE A GLOBAL REGENERATIVE THERAPEUTICS COMPANY
MYELODYSPLASTIC AND MYELOPROLIFERATIVE
MYELODYSPLASTIC AND MYELOPROLIFERATIVE DISORDERS Pediatric Hemato-Oncology Division Medical Faculty University of Sumatera Utara 1 MYELODYSPLASIA SYNDROME A group of disorder defect in hematopoetic cell
POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): October 1, 2014 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
Sub-Class Code Sub-Classification Other code Other classification. Bone Marrow failures including 7 Aplastic Anaemia 77 Other 1 Acquired
ification ification Other code Other classification Absence of T & B cells SCID 8 Inherited Disorders 1 Primary immune deficiencies Absence of T, normal B cell SCID 8 Inherited Disorders 1 Primary immune
Policy #: 190 Original policy date: 6/1/2010 Page: 1 of 9 Revised date: 5/1/2012
MEDICAL POLICY Policy #: 190 Original policy date: 6/1/2010 Page: 1 of 9 Revised date: 5/1/2012 Title Allogeneic Hematopoietic Stem Cell Transplantation for Genetic Diseases and Acquired Description Hematopoietic
Allogeneic Hematopoietic Cell Transplantation for Genetic Diseases and Acquired Anemias
Medical Policy Manual Transplant, Policy No. 45.25 Allogeneic Hematopoietic Cell Transplantation for Genetic Diseases and Acquired Anemias Next eview: January 2019 Last eview: February 2018 Effective:
Allogeneic Hematopoietic Stem-Cell Transplantation for Genetic Diseases and Acquired Anemias
Allogeneic Hematopoietic Stem-Cell Transplantation for Genetic Diseases and Acquired Anemias Policy Number: 8.01.22 Last Review: 7/2014 Origination: 7/2002 Next Review: 7/2015 Policy Blue Cross and Blue
Sub-Class Code Sub-Classification Other code Other classification. Bone Marrow failures including 7 Aplastic Anaemia 77 Other 1 Acquired
ification Sub- Sub-ification Other code Other classification Absence of T & B cells SCID 8 Inherited Disorders 1 Primary immune deficiencies Absence of T, normal B cell SCID 8 Inherited Disorders 1 Primary
Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:
Medical Policy Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Type: Medical Necessity and Investigational / Experimental Policy Specific Section:
babycell.in SMS Babycell to 56677
1800-209-0309 babycell.in SMS Babycell to 56677 R R One life. One opportunity. Congratulations on your pregnancy! Your little miracle will soon make your world more beautiful and happier. As expecting
Sub-Class Code Sub-Classification Other code Other classification. Bone Marrow failures including 7 Aplastic Anaemia 77 Other 1 Acquired
ification Sub- Sub-ification Other code Other classification Absence of T & B cells SCID 8 Inherited Disorders 1 Primary immune deficiencies Absence of T, normal B cell SCID 8 Inherited Disorders 1 Primary
MEDICAL POLICY SUBJECT: ALLOGENEIC STEM CELL TRANSPLANTATION
MEDICAL POLICY SUBJECT: ALLOGENEIC STEM CELL PAGE: 1 OF: 13 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy
No Other Company Discloses Higher Transplant Survival Rate. Infusions For Emerging Treatments. Date of Use. Recipient Age (yrs)
Units Used In Transplants/Infusions No Other Company Discloses Higher Transplant Survival Rate Family Banking Provides Exclusive Access To Emerging Treatments With Your Own Cells 175 85% Type 1 Diabetes
Immunodeficiency. By Dr. Gouse Mohiddin Shaik
Immunodeficiency By Dr. Gouse Mohiddin Shaik Immunodeficieny Immunodeficiency is failure of immune system to protect against disease or malignency Immunodeficiency is of two types Primary Secondary immunodeficiency
Allogeneic Hematopoietic Stem-Cell Transplantation for Genetic Diseases and Acquired Anemias. Original Policy Date
MP 7.03.15 Allogeneic Hematopoietic Stem-Cell Transplantation for Genetic Diseases and Acquired Anemias Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date
National Medical Policy
National Medical Policy Subject: Policy Number: Stem Cell Transplantation in Adult Patients NMP263 Effective Date*: April 2006 Updated: June 2017 This National Medical Policy is subject to the terms in
Contents SECTION 1: PHYSIOLOGY OF BLOOD
Contents SECTION 1: PHYSIOLOGY OF BLOOD Chapter 1: Overview of Physiology of Blood 1 Normal Haematopoiesis 1 Red Blood Cells 6 White Blood Cells 15 Immune System 27 Megakaryopoiesis 32 Normal Haemostasis
2010 Hematopoietic and Lymphoid ICD-O Codes - Alphabetical List THIS TABLE REPLACES ALL ICD-O-3 Codes
Acute basophilic leukemia 9870/3 Acute biphenotypic leukemia [OBS] 9805/3 Acute erythroid leukemia 9840/3 Acute megakaryoblastic leukemia 9910/3 Acute monoblastic and monocytic leukemia 9891/3 Acute myeloid
2012 Hematopoietic and Lymphoid ICD-O Codes - Numerical List THIS TABLE REPLACES ALL ICD-O-3 Codes
Malignant lymphoma, NOS 9590/3 Non-Hodgkin lymphoma, NOS 9591/3 B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma 9596/3 Primary
Retired Not for Data Submission
National Marrow Donor Program Baseline and Transplant Data Unrelated Sequence Number: Date Received: Research blood samples should be collected before initiation of preparative regimen and sent to Blood
Pediatric Hematology-Oncology
Pediatric Hematology-Oncology Content Outline In-Training, Initial Certification, and Maintenance of Certification Exams Effective for exams administered beginning April 1, 2019 THE AMERICAN BOARD of PEDIATRICS
Bin them or bank them?
Bin them or bank them? What are stem cells? Single cells that can Differentiate into any one of 220 different specialised cells in the body or......replicate themselves Stem cells are often called master
MEDICAL HISTORY FORM ADMINISTRATION INSTRUCTIONS
ADMINISTRATION INSTRUCTIONS CONFIRM THE STUDY BAR CODE ON PAGES 1 THROUGH 6 OF THIS FORM DO NOT PLACE A STUDY BAR CODE LABEL ON THIS INSTRUCTION PAGE. Interview Instructions The interview should be conducted
HEMATOLOGY Maintenance of Certification (MOC) Examination Blueprint
HEMATOLOGY Maintenance of Certification (MOC) Examination Blueprint ABIM invites diplomates to help develop the Hematology MOC exam blueprint Based on feedback from physicians that MOC assessments should
Hematopoietic Stem Cell Therapy
Hematopoietic Stem Cell Therapy Grace Totoe, MBChB, SBB CME August 2012 Accra-Ghana Hematopoietic Stem Cells Cells capable of self renewal and differentiation into all blood cell lineages Objectives Historical
1. Penchansky Pediatric Bone Marrow
1. Penchansky Pediatric Bone Marrow Springer-Verlag Berlin Heidelberg GmbH Lila Penchansky Pe Bo la rle e Marrow With 356 Figures in 530 Separate Illustrations, Mostly in Color " Springer Professor LI
An Overview of Blood and Marrow Transplantation
An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit
YEREVAN STATE MEDICAL UNIVERSITY DEPARTMENT OF HEMATOLOGY COURSE DESCRIPTION HEMATOLOGY
1. Module/unit Code II. 1.2. 2. Module/unit Title Hematology 3. Subject Field Internal Diseases Group 4. Faculty/Department General Medicine, Department of Hematology 5. Programme(s) to which the Doctor
ASPHO 2019 Review Course January 31-February 2, 2019
ASPHO 2019 Review Course January 31-February 2, 2019 ABP Content Outline Topics by Date and Speaker For additional information, see the ABP Content Outline and the ABP Content Outline with Speaker Assignments.
Contractor Name: Novitas Solutions, Inc. Contractor Number: Contractor Type: MAC A. LCD ID Number: L35032 Status: A-Approved
LCD for Flow Cytometry (L35032) Contractor Name: Novitas Solutions, Inc. Contractor Number: 12501 Contractor Type: MAC A LCD ID Number: L35032 Status: A-Approved Contractor Information LCD Information
Myelodysplastic Syndrome: Let s build a definition
1 MDS: Diagnosis and Treatment Update Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine Weill Medical College of Cornell University The New York Presbyterian Hospital Myelodysplastic
Regence. Next Review: 08/2019 Last Review: 08/2018 Medicare Link(s) Revised: 10/01/2018 IMPORTANT REMINDER
Regence Medicare Advantage Policy Manual Policy ID: M-TRA45 Stem Cell / Bone Marrow Transplants Published: 10/01/2018 Next Review: 08/2019 Last Review: 08/2018 Medicare Link(s) Revised: 10/01/2018 IMPORTANT
Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand
Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand This list provides indications for the majority of adult BMTs that are performed in New Zealand. A small number of BMTs
Medical Policy Title ALLOGENEIC HEMATOPOIETIC (STEM) CELL TRANSPLANTATION Policy Number
Page: 1 of 13 MEDICAL POLICY MEDICAL POLICY DETAILS Medical Policy Title ALLOGENEIC HEMATOPOIETIC (STEM) CELL TRANSPLANTATION Policy Number 7.02.02 Category Transplants Effective Date 11/19/99 Revised
Bone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint
Bone Marrow Protocol applies to acute leukemias, myelodysplastic syndromes, myeloproliferative disorders, chronic lymphoproliferative disorders, malignant lymphomas, plasma cell dyscrasias, histiocytic
a d u lt s t e m c e l l t r a n s p l a n tat i o n p r o g r a m i n f o r m at i o n f o r pay e r s a n d r e f e r r e r s
a d u lt s t e m c e l l t r a n s p l a n tat i o n p r o g r a m i n f o r m at i o n f o r pay e r s a n d r e f e r r e r s Summer 2017 For more information, visit www.dfbwcc.org/bmt. o u r expertise
HEALTH SERVICES POLICY & PROCEDURE MANUAL
PAGE 1 of 6 PURPOSE To establish basic understanding of indications and contraindications for transplantation of various organs. POLICY The N.C. Department of Correction, Division of Prisons, Health Services
Stem cells. -Dr Dinesh Bhurani, MD, DM, FRCPA. Rajiv Gandhi Cancer Institute, Delhi, -Director, Department of Haematology and BMT
Stem cells -Dr Dinesh Bhurani, MD, DM, FRCPA -Director, Department of Haematology and BMT Rajiv Gandhi Cancer Institute, Delhi, Flow of presentation Update on stem cell uses Haematopoietic stem cell transplantation
List of Qualifying Conditions
List of Qualifying Conditions Cancer Conditions 1) Adrenal cancer 2) Bladder cancer 3) Bone cancer all forms 4) Brain cancer 5) Breast cancer 6) Cervical cancer 7) Colon cancer 8) Colorectal cancer 9)
Overview of Aplastic Anemia. Overview of Aplastic Anemia. Epidemiology of aplastic anemia. Normal hematopoiesis 10/6/2017
Overview of Aplastic Anemia Overview of Aplastic Anemia Peter Westervelt, MD, PhD Professor of Medicine Chief, BMT/Leukemia Section Washington University School of Medicine Epidemiology Normal hematopoiesis
Bone marrow failure. By Zahraa Nasooh Al_Saaty
Bone marrow failure By Zahraa Nasooh Al_Saaty Pancytopenia : Pancytopenia describes a reduction in the blood count of all the major cell lines-red cells,white cell and platelets. It has several causes
MOC HEM - General Hematopathology (Mandatory 50-Question Module)
MOC HEM - General Hematopathology (Mandatory 50-Question Module) acute monoblastic/monocytic leukemia infectious mononucleosis adult T cell leukemia/lymphoma in situ follicular lymphoma ALL; phenotypes
MOC HEM - General Hematopathology (Mandatory 50-Question Module)
MOC HEM - General Hematopathology (Mandatory 50-Question Module) acute monoblastic/monocytic leukemia infectious mononucleosis adult T cell leukemia/lymphoma in situ follicular lymphoma ALL; phenotypes
Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation. December Reference : NHSCB/B4/a/1
Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation December 2012 Reference : NHSCB/B4/a/1 NHS Commissioning Board Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation
Effective Health Care Program
Comparative Effectiveness Review Number 48 Effective Health Care Program Hematopoietic Stem-Cell Transplantation in the Pediatric Population Executive Summary Background Hematopoietic stem-cell transplantation
CERSI MTG BALTIMORE,MD MAY 8,2013 ARNOLD I CAPLAN
CERSI MTG BALTIMORE,MD MAY 8,2013 ARNOLD I CAPLAN The Science of MSCs & REGENERATIVE MEDICINE : CELL-BASED THERAPY = the NEW MEDICINE. ARNOLD I. CAPLAN, PhD Baltimore, MD May 8, 2013 Case Western Reserve
MDS 101. What is bone marrow? Myelodysplastic Syndrome: Let s build a definition. Dysplastic? Syndrome? 5/22/2014. What does bone marrow do?
101 May 17, 2014 Myelodysplastic Syndrome: Let s build a definition Myelo bone marrow Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine What is bone marrow? What does bone
SAUDI FELLOWSHIP TRAINING PROGRAM. Adult Haematology. Final Written Examination 2019
SAUDI FELLOWSHIP TRAINING PROGRAM Adult Haematology Final Written Examination 2019 Examination Format: A. The Saudi fellowship specialty final written examination shall consist of one paper with 80-120
Hematology Page 1 of 8
Hematology Page 1 of 8 Hematology Major Category Code Headings Revised 12/17 1 Basic methodology and test armamentarium 20000 2 Normal hematopoiesis & hemostasis 20100 3 RBC disorders, non-neoplastic 20340
DEPARTMENT OF CLINICAL HEMATOLOGY
DEPARTMENT OF CLINICAL HEMATOLOGY What is blood? Blood is the vital fluid of the body, which performs diverse functions from delivering oxygen to each and every cell of the body to fighting against infections
Tim R. Randolph. PhD, MT(ASCP) Chair and Associate Professor Department of Biomedical Laboratory Science Saint Louis University
Tim R. Randolph. PhD, MT(ASCP) Chair and Associate Professor Department of Biomedical Laboratory Science Saint Louis University Anemias Over 30 types Myeloproliferative Neoplasm Polycythemia Leukemia AML:M6
Saudi Fellowship Training Program. Final Written Examination of Adult Hematology 2018
Saudi Fellowship Training Program Final Written Examination of Adult Hematology 2018 Objectives: Determine the quantity and quality of a hematologist s knowledge base ranked as competent, so that the individual
Rare Disease Day Brussels, 1 March
Research activities in Europe: Trends and determinants Rare Disease Day Brussels, 1 March 2010 Research Death valley Development Collaboration clinicians / researchers Pharmaceutical Innovation / Performance
Combinations of morphology codes of haematological malignancies (HM) referring to the same tumour or to a potential transformation
Major subgroups according to the World Health Organisation (WHO) Classification Myeloproliferative neoplasms (MPN) Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or
MDS: Who gets it and how is it diagnosed?
MDS: Who gets it and how is it diagnosed? October 16, 2010 Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine Weill Medical College of Cornell University The New York Presbyterian
Supplementary Materials for
Supplementary Materials for A Clinical Trial for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes Not Eligible for Standard Clinical Trials Table of Contents Content Page Supplementary
Pathology of Hematopoietic and Lymphoid tissue
CONTENTS Pathology of Hematopoietic and Lymphoid tissue White blood cells and lymph nodes Quantitative disorder of white blood cells Reactive lymphadenopathies Infectious lymphadenitis Tumor metastasis
Stem cell applications- Cord blood, Cord tissue, Fat tissue
Stem cell applications- Cord blood, Cord tissue, Fat tissue Annual General Meeting of Shareholders 18 May 2011 Arnoud van Tulder Chief Executive Officer 1 Latest news about stem cells (1/3) New heartwithownstem
BMTCN Review Course Basic Concepts and Indications for Transplantation. David Rice, PhD, RN, NP
BMTCN Review Course Basic Concepts and Indications for Transplantation March 16, 2017 David Rice, PhD, RN, NP Director, Professional Practice and Education No disclosures Objectives Describe basic concepts
Hematology Unit Lab 2 Review Material
Objectives Hematology Unit Lab 2 Review Material - 2018 Laboratory Instructors: 1. Assist students during lab session Students: 1. Review the introductory material 2. Study the case histories provided
Hematopoetic Stem Cell Therapies in TURKIYE
Hematopoetic Stem Cell Therapies in TURKIYE World Location of transplant centers participating in CIBMTR (2010) Dr. Mustafa ÇETİN Mustafa CETIN, M.D. Erciyes University Medical Faculty Kayseri-TURKIYE
Table of Contents. 1.0 Description of the Procedure, Product, or Service... 1
Allogeneic Hematopoietic & Bone Clinical Coverage Policy No: 11A-5 Marrow Transplant for Genetic Amended Date: October 1, 2015 Diseases and Acquired Anemias Table of Contents 1.0 Description of the Procedure,
Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas. James J. Stark, MD, FACP
Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS
Clinical Policy Title: Bone marrow transplants
Clinical Policy Title: Bone marrow transplants Clinical Policy Number: 14.02.06 Effective Date: January 1, 2016 Initial Review Date: November 18, 2015 Most Recent Review Date: November 16, 2016 Next Review
What s New in Newborn Screening?
What s New in Newborn Screening? Funded by: Illinois Department of Public Health Information on Newborn Screening Newborn screening in Illinois is administered by the Illinois Department of Public Health.
5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA
AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana
CLIC Sargent Eligibility Criteria
1 Eligibility Criteria DOCUMENT GOVERNANCE: Eligibility criteria Produced by J. Hawkins & Grants Team Sponsored by Dara de Burca Version Approval by Executive Team 10 th June 2014 Board of Trustees 3 rd
HEMATOLOGIC MALIGNANCIES BIOLOGY
HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION
Leukocyte Disorders. Dr Alauldeen Mudhafar Zubair
Leukocyte Disorders Dr Alauldeen Mudhafar Zubair Composition of blood Specialized connective tissue Blood cells (formed elements) suspended in plasma Blood volume: 5-6 liters (approx 1.5 gal) in males
Immunodeficiency and Skin (September 21, 2018) By (Arti Nanda, MD, DNBE [Kuwait])
![Immunodeficiency and Skin (September 21, 2018) By (Arti Nanda, MD, DNBE [Kuwait])](/thumbs/90/103062332.jpg "Immunodeficiency and Skin (September 21, 2018) By (Arti Nanda, MD, DNBE [Kuwait])")
Immunodeficiency and Skin (September 21, 2018) By (Arti Nanda, MD, DNBE [Kuwait]) Immune deficiency refers to a state in which part of immune system is missing or defective resulting into an inability
HEMATOPOIETIC STEM CELL TRANSPLANT
HEMATOPOIETIC STEM CELL TRANSPLANT Protocol: TRP011 Effective Date: February 1, 2018 Table of Contents Page RELATIVE CONTRAINDICATIONS... 1 GENERAL INFORMATION... 3 CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY...
2 nd step do Bone Marrow Study If possible both the aspiration and
Blood Malignancies-I Prof. Herman Hariman,SpPK a (KH). Ph.D.(U.K) Prof. Dr. Adikoesoema Aman, SpPK (KH) Dept. Clinpath, FK-USU First do the Full Blood Count Hb, WBCS, Platelets Morphology!! Such as blasts,
Luke Droney IMMUNOGLOBULIN LEVELS AND FUNCTION
IMMUNOGLOBULIN LEVELS AND FUNCTION Interpret changes in immunoglobulin levels within the clinical context including - Immunodeficiency - Disorders characterised by hypergammaglobulinaemia, rheumatoid arthritis,